University of Vienna, Department of Medicinal Chemistry, Althanstrasse 14, 1090, Vienna, Austria.
J Med Chem. 2012 Apr 12;55(7):3261-73. doi: 10.1021/jm201705f. Epub 2012 Mar 27.
The drug efflux pump P-glycoprotein (P-gp) has been shown to promote multidrug resistance (MDR) in tumors as well as to influence ADME properties of drug candidates. Here we synthesized and tested a series of benzophenone derivatives structurally analogous to propafenone-type inhibitors of P-gp. Some of the compounds showed ligand efficiency and lipophilic efficiency (LipE) values in the range of compounds which entered clinical trials as MDR modulators. Interestingly, although lipophilicity plays a dominant role for P-gp inhibitors, all compounds investigated showed LipE values below the threshold for promising drug candidates. Docking studies of selected analogues into a homology model of P-glycoprotein suggest that benzophenones show an interaction pattern similar to that previously identified for propafenone-type inhibitors.
药物外排泵 P-糖蛋白 (P-gp) 已被证明可促进肿瘤的多药耐药性 (MDR),并影响候选药物的 ADME 性质。在这里,我们合成并测试了一系列与 P-gp 抑制剂结构类似的苯并二酮衍生物。一些化合物表现出与作为 MDR 调节剂进入临床试验的化合物相当的配体效率和脂效率 (LipE) 值。有趣的是,尽管亲脂性对 P-gp 抑制剂起着主导作用,但所研究的所有化合物的 LipE 值均低于有前途的药物候选物的阈值。对选定类似物进行对接研究,进入 P-糖蛋白同源模型,表明苯并二酮类化合物表现出与先前鉴定的普罗帕酮型抑制剂相似的相互作用模式。